Clinical trial registry record

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 5, 2014.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01016873
Last registry update
December 5, 2014
Status
Completed
Phase
Phase 2
Sponsor
Oraya Therapeutics, Inc.
Enrollment
230
Countries
Austria, Czechia, Germany, Italy, United Kingdom
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
230
Population
ALL · 50 Years
Duration
2009-11-01 to 2014-04-01
Intervention
IRay
Comparator
Not reported
Outcomes measured
Number of Lucentis® Injections Up To And Including Week 52 — During the first 52 weeks.; Change in Mean Visual Acuity (VA) — Weeks 12, 28, 52 and 104.; Percentage (Pct.) of Patients (Pts.) Losing < 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.) — W…; Percentage (Pct.) of Patients (Pts.) Gaining ≥ 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.) —…; Percentage (Pct.) of Patients (Pts.) Gaining ≥ 0 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.) — W…; Time From Mandatory Injection at Day 0 to the First PRN Injection. — 52 Weeks; Total Number (No.) of Lucentis® Injections (Inject.) During The First 12, 28, and 104 Weeks. — Week 12, 28, and 104; Mean Change in Choroidal Neovascularization (CNV) as % of Lesion on Fluorescein Angiography (FA) From Baseline to Week…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON